Skip to main content

Table 1 Clinical characteristics of participants in individual groups in the current study

From: P-tau and neurodegeneration mediate the effect of β-amyloid on cognition in non-demented elders

  CN (n = 370) MCI (n = 623) p value
Age (years) 73.78 ± 5.91 72.42 ± 7.53 0.012
Gender (F/M) 194/176 256/366 0.001
Education (years) 16.39 ± 2.62 16.05 ± 2.76 0.081
APOE ε4 carriers (%) 27.84% 49.12% < 0.001
CSF measures
 Aβ42 200.34 ± 50.95 171.70 ± 52.28 < 0.001
 p-tau 32.13 ± 18.40 39.07 ± 22.38 < 0.001
 t-tau 67.51 ± 32.16 90.56 ± 54.82 < 0.001
 Neurogranin 379.95 ± 284.78 508.58 ± 343.28 < 0.001
 sTREM2 4104.09 ± 2122.88 4448.60 ± 2285.17 0.508
 YKL-40 392.56 ± 127.99 393.71 ± 131.49 0.966
Plasma NFL 34.32 ± 21.96 39.20 ± 22.85 < 0.001
MRI measures
 Whole brain 1040346.1 ± 104238.7 1047243.7 ± 109038.5 0.411
 Hippocampus 7467.2 ± 851.0 6867.8 ± 1142.1 < 0.001
 Entorhinal 3854.9 ± 610.2 3553.4 ± 724.3 < 0.001
 Mid temporal 20342.2 ± 2649.5 19895.1 ± 2860.6 0.051
Cognitive composite measures
 Memory function 1.05 ± 0.57 0.20 ± 0.69 < 0.001
 Executive function 0.79 ± 0.82 0.23 ± 0.88 < 0.001
 Language 0.81 ± 0.71 0.21 ± 0.77 < 0.001
 Visuospatial functioning 0.20 ± 0.60 − 0.06 ± 0.75 < 0.001
  1. Categorical variables are reported as numbers and percentages; continuous variables are reported as means ± SDs
  2. Abbreviations: CN normal controls, MCI mild cognitive impairment, M male, F female, APOE ε4 apolipoprotein E4, CSF cerebrospinal fluid, amyloid-β, p-tau phosphorylated tau, t-tau total tau, sTREM2 soluble triggering receptor on myeloid cells 2, NFL neurofilament light, MRI magnetic resonance imaging